The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup  randomized phase III clinical trial.
Patrice P. Carde
No relevant relationships to disclose
Matthias Karrasch
No relevant relationships to disclose
Catherine Fortpied
No relevant relationships to disclose
Pauline Brice
No relevant relationships to disclose
Hussein Mustafa Khaled
No relevant relationships to disclose
Denis Caillot
No relevant relationships to disclose
Isabelle Gaillard
No relevant relationships to disclose
Serge Bologna
No relevant relationships to disclose
Christophe Ferme
No relevant relationships to disclose
Pieternella Lugtenburg
No relevant relationships to disclose
Franck Morschhauser
No relevant relationships to disclose
Igor Aurer
No relevant relationships to disclose
Bertrand Coiffier
No relevant relationships to disclose
Guy Cantin
No relevant relationships to disclose
Matthew D. Seftel
No relevant relationships to disclose
Max Wolf
No relevant relationships to disclose
Bengt Glimelius
No relevant relationships to disclose
Anna Sureda
No relevant relationships to disclose
Nicolas Mounier
No relevant relationships to disclose